MA41083A1 - Compositions pharmaceutiques pour thérapie combinée - Google Patents

Compositions pharmaceutiques pour thérapie combinée

Info

Publication number
MA41083A1
MA41083A1 MA41083A MA41083A MA41083A1 MA 41083 A1 MA41083 A1 MA 41083A1 MA 41083 A MA41083 A MA 41083A MA 41083 A MA41083 A MA 41083A MA 41083 A1 MA41083 A1 MA 41083A1
Authority
MA
Morocco
Prior art keywords
insulin
blood
glucose
pharmaceutical compositions
combination therapy
Prior art date
Application number
MA41083A
Other languages
English (en)
Inventor
Mark Pruzanski
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MA41083A1 publication Critical patent/MA41083A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant une combinaison d'un agoniste de fxr et au moins un agent thérapeutique supplémentaire qui abaisse le niveau de glucose dans le sang, stimule la sécrétion de l'insuline et/ou augmente la sensibilité à l'insuline. La présente invention concerne l'utilisation de la composition pharmaceutique pour le traitement ou la prévention d'une maladie ou affection à médiation par fxr, comme nafld ou nash, une maladie ou un état lié à un taux élevé de glucose dans le sang, une sécrétion diminuée de l'insuline et/ou une sensibilité diminuée à l'insuline, comme l'hyperglycémie, le diabète, l'obésité, et la résistance à l'insuline, ou pour abaisser le taux de glucose dans le sang, stimuler la sécrétion d'insuline, et/ou augmenter la sensibilité à l'insuline.
MA41083A 2015-04-07 2016-04-06 Compositions pharmaceutiques pour thérapie combinée MA41083A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562144040P 2015-04-07 2015-04-07
PCT/US2016/026146 WO2016164413A1 (fr) 2015-04-07 2016-04-06 Compositions pharmaceutiques pour thérapie combinée

Publications (1)

Publication Number Publication Date
MA41083A1 true MA41083A1 (fr) 2018-05-31

Family

ID=57072872

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41083A MA41083A1 (fr) 2015-04-07 2016-04-06 Compositions pharmaceutiques pour thérapie combinée

Country Status (23)

Country Link
US (1) US10894054B2 (fr)
EP (1) EP3280421B1 (fr)
JP (1) JP6879931B2 (fr)
KR (1) KR20170132879A (fr)
CN (1) CN107613986A (fr)
AR (1) AR104195A1 (fr)
AU (1) AU2016246524B2 (fr)
BR (1) BR112017021311A2 (fr)
CA (1) CA2981507A1 (fr)
CL (2) CL2017002538A1 (fr)
CO (1) CO2017010292A2 (fr)
CR (1) CR20170456A (fr)
EA (1) EA036757B1 (fr)
EC (1) ECSP17073004A (fr)
IL (2) IL254772A0 (fr)
MA (1) MA41083A1 (fr)
MX (1) MX2017012893A (fr)
NI (1) NI201700121A (fr)
PE (1) PE20180034A1 (fr)
SV (1) SV2017005539A (fr)
TN (1) TN2017000426A1 (fr)
TW (1) TW201642869A (fr)
WO (1) WO2016164413A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US10174289B2 (en) 2014-05-28 2019-01-08 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
WO2016061464A1 (fr) 2014-10-17 2016-04-21 Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center Modèle in vivo d'intestin grêle humain faisant intervenir des cellules souches pluripotentes et ses procédés de fabrication et d'utilisation
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
AU2017252015A1 (en) 2016-04-19 2018-11-08 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
US11066650B2 (en) 2016-05-05 2021-07-20 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
KR102546194B1 (ko) * 2016-11-04 2023-06-21 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
AU2017373767B2 (en) 2016-12-05 2021-09-16 Children's Hospital Medical Center Colonic organoids and methods of making and using same
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva
KR20210002573A (ko) * 2018-04-24 2021-01-08 주식회사 피에이치파마 간 질환에 호중구 엘라스타제 저해제의 사용
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US20210393662A1 (en) * 2018-10-18 2021-12-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
EP3886892A1 (fr) * 2018-11-30 2021-10-06 UREKA Sarl Composés foldamères de peptide-oligourée et leurs procédés d'utilisation
AU2020247991A1 (en) * 2019-03-26 2021-10-21 Intercept Pharmaceuticals, Inc. Methods of diagnosis and treatment of liver diseases using obeticholic acid
US20220288054A1 (en) * 2019-04-04 2022-09-15 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2021029656A1 (fr) * 2019-08-14 2021-02-18 주식회사 바이오톡스텍 Composition pharmaceutique pour la prévention ou le traitement de la stéatohépatite non alcoolique, contenant un dérivé d'hydroquinone et de l'acide obéticholique
WO2023225507A1 (fr) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Procédés et compositions pour traiter un excès de glucocorticoïdes
WO2023240204A2 (fr) * 2022-06-08 2023-12-14 Kojin Therapeutics, Inc. Méthodes et compositions pour amorcer, réguler et moduler la perte de poids et leurs applications thérapeutiques

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
DE69940958D1 (de) 1998-12-23 2009-07-16 Glaxo Group Ltd Bestimmungsmethode fur liganden der nuklearen rezeptoren
AU2409600A (en) 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
KR100455635B1 (ko) 1999-03-29 2004-11-06 에프. 호프만-라 로슈 아게 글루코키나제 활성화제
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
US7138390B2 (en) 2001-03-12 2006-11-21 Intercept Pharmaceuticals Steroids as agonists for FXR
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
WO2003086303A2 (fr) 2002-04-12 2003-10-23 The University Of Chicago Agonistes de recepteur active frx (farnesoid x receptor)
CA2549015A1 (fr) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. C-glycosides heterocycliques fusionnes substitues
CA2549017A1 (fr) 2003-08-01 2005-02-10 Mona Patel Indazoles-o-glucosides substitues
EP1568706A1 (fr) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Nouveau agonist steroidal pour FXR
HUE032928T2 (hu) 2004-03-12 2017-11-28 Intercept Pharmaceuticals Inc Fibrózis kezelése FXR-ligandumok alkalmazásával
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
EP1971362B1 (fr) * 2005-08-19 2014-12-03 Amylin Pharmaceuticals, LLC Exendin pour le traitement du diabete et la reduction de poids corporel
WO2007076260A2 (fr) * 2005-12-19 2007-07-05 Smithkline Beecham Corporation Agonistes de recepteur de farnesoide x
JP2010517931A (ja) 2006-02-14 2010-05-27 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体
EP2029547B1 (fr) 2006-05-24 2010-04-28 Eli Lilly And Company Agonistes de récepteur de farnesoide x
CA2651373A1 (fr) 2006-05-24 2007-12-06 Eli Lilly And Company Composes et methodes de modulation de fxr
CA2656320C (fr) 2006-06-27 2015-04-28 Intercept Pharmaceuticals, Inc. Derives de l'acide biliaire en tant que des ligands de fxr pour la prevention ou le traitement de maladies ou conditions mediees par le fxr
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
EP1894928A1 (fr) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Composes heterocycliques de liaison au fxr
EP1894924A1 (fr) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Composés hétérocycliques de liason du FXR
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (fr) 2008-04-18 2009-10-21 Merck Sante Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR
US20100056546A1 (en) 2008-09-04 2010-03-04 Auspex Pharmaceuticals, Inc. Sulfonylurea inhibitors of atp-sensitive potassium channels
WO2010138535A1 (fr) 2009-05-27 2010-12-02 Bristol-Myers Squibb Company Méthodes pour le traitement de diabète de type 2 chez des patients résistant à un traitement précédent avec d'autres médicaments anti-diabétiques employant un inhibiteur sglt2 et compositions associées
EP2289883A1 (fr) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Nouveaux composés modulant l'activité du recepteur FXR (NR1H4)
AU2011220748B2 (en) 2010-02-24 2015-11-05 Relypsa, Inc. Amine polymers for use as bile acid sequestrants
WO2011150285A1 (fr) 2010-05-26 2011-12-01 Adm Tronics Unlimited Inc. Appareil et procédé de mesure du débit urinaire
EP3593802A3 (fr) * 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Inhibiteurs de recyclage d'acide biliaire et satiogènes pour le traitement du diabète, de l'obésité et des conditions gastro-intestinales inflammatoires
EP2617514A4 (fr) 2010-09-15 2018-01-03 Sumitomo Electric Industries, Ltd. Procédé de traitement au laser
WO2012106581A1 (fr) 2011-02-03 2012-08-09 The University Of Chicago Inhibiteur de fxr, agent séquestrant d'acide biliaire en tant que polythérapie pour la réduction du cholestérol
DK3336097T3 (da) 2012-06-19 2020-09-28 Intercept Pharmaceuticals Inc Fremstilling af ikke-krystallinsk obeticholsyre
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
PT3360881T (pt) 2013-05-14 2021-02-19 Intercept Pharmaceuticals Inc Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e conjugados de aminoácidos dos mesmos como moduladores do recetor farnesoide x
DK3253382T3 (da) * 2015-02-06 2022-02-14 Intercept Pharmaceuticals Inc Farmaceutiske sammensætninger til kombinationsterapi

Also Published As

Publication number Publication date
EA036757B1 (ru) 2020-12-17
CO2017010292A2 (es) 2018-01-05
CR20170456A (es) 2018-06-13
JP6879931B2 (ja) 2021-06-02
US10894054B2 (en) 2021-01-19
MX2017012893A (es) 2018-01-15
IL268316A (en) 2019-09-26
EP3280421A4 (fr) 2019-08-28
AR104195A1 (es) 2017-07-05
NI201700121A (es) 2018-01-10
EA201792203A1 (ru) 2018-02-28
EP3280421A1 (fr) 2018-02-14
AU2016246524A1 (en) 2017-10-26
ECSP17073004A (es) 2018-02-28
CA2981507A1 (fr) 2016-10-13
CN107613986A (zh) 2018-01-19
BR112017021311A2 (pt) 2018-06-26
JP2018510900A (ja) 2018-04-19
AU2016246524B2 (en) 2021-04-01
IL268316B (en) 2022-02-01
KR20170132879A (ko) 2017-12-04
CL2017002538A1 (es) 2018-04-20
CL2018001007A1 (es) 2018-06-15
TN2017000426A1 (en) 2019-04-12
PE20180034A1 (es) 2018-01-09
EP3280421B1 (fr) 2023-12-27
TW201642869A (zh) 2016-12-16
IL254772A0 (en) 2017-12-31
US20180117065A1 (en) 2018-05-03
SV2017005539A (es) 2019-01-18
WO2016164413A1 (fr) 2016-10-13

Similar Documents

Publication Publication Date Title
MA41083A1 (fr) Compositions pharmaceutiques pour thérapie combinée
Jantaratnotai et al. The interface of depression and obesity
Malhotra et al. Metabolic syndrome in schizophrenia
MA46219A (fr) Composés de co-agonistes du glucagon et du glp-1
EA200870365A1 (ru) Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ
MA40709B1 (fr) Dérivé du glucagon à stabilité améliorée
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
BR112015019039A8 (pt) compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina
Ilyina et al. Efficacy of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, delivered in a single spray, for the treatment of seasonal allergic rhinitis: results from Russia
EA202190477A1 (ru) Ацилированные миметики кальцитонина
EA201691420A1 (ru) Композиции енолазы 1 (eno1) и их применение
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
MA34106B1 (fr) Combinaison de composés organiques
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
JP2015517534A5 (fr)
MA32012B1 (fr) Octahydroquinolizines destinees au traitement du diabete
Özer et al. Effectiveness of plantar fascia-specific stretching exercises in plantar fasciitis
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas
Kolikonda Myopathy: case report
BR112021017683A2 (pt) Inibidores da atividade de pelo menos uma proteína pertencente à família hsp70 e / ou inibidores da atividade da proteína grp78 para uso no tratamento da resistência a insulina e / ou das patologias decorrentes ou relacionadas à mesma, composição, e método para o diagnóstico de resistência a insulina em um ser humano
Du Plessis et al. Acute changes in haematocrit leading to polycythaemia in late-onset hypogonadism patients that receive testosterone replacement therapy: a South African study
McDonell Persistent irritability: case report
MA56041A (fr) Compositions comprenant des acides gras cétylés, destinées à être utilisées dans le traitement de la muqueuse gastrique, du diabète et de l'hyperglycémie
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения